It was very tight to get all my questions answered in 30 minutes, but I tried to get as much clarity as I could, let’s get straight to the questions and answers. Q: Why did you decide to expand the 103 study from 11 to 20 patients? A: To adjust the 4-5 & 6-7 years […]
So the sector did not dump into new lows, which is good but we are still a really bad day or a couple of regular bad days away from breaking new lows. This $126 level on the XBI has acted as support a number of times (in that we have bounced off of it) but […]
It is really starting to look like we have set another lower high and are on our way to set another lower low. I had some hope that we were getting some upside momentum but this just reinforces my view that you need to respect the trend until it is broken and while we have […]
We remain in the same spot with the sector. It has not really given us the clear signal but we really need to break above that $140 level to ensure that we have not made a clear lower high. There is also another potential higher low being setup around $135.66 or so. I am not […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.